The study presented at the 2023 annual meeting of the American Society for Reproductive Medicine discusses the underreporting of adverse events related to embryo transfer catheters (ETCs) to the FDA. The research emphasizes the importance of monitoring and reporting such incidents to ensure patient safety. Key highlights include the identification of adverse events, the distribution of problems across different ETC brands, and the impact on patient care. Recommendations for heightened surveillance and improved reporting are provided to address these issues.
To Another Language
from source content
www.medscape.com
Key Insights Distilled From
by Meg Barbor at www.medscape.com 10-25-2023
https://www.medscape.com/viewarticle/997719Deeper Inquiries